These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 1865201

  • 1. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM, Heuser IJ, Baronti F, Giuffra M, Conant K, Davis TL, Chase TN.
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
    [Abstract] [Full Text] [Related]

  • 2. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 Jun; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 6. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
    Jenner P, Katzenschlager R.
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
    [Abstract] [Full Text] [Related]

  • 7. Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
    Jenner P, Falup-Pecurariu C, Leta V, Verin M, Auffret M, Bhidayasiri R, Weiss D, Borovečki F, Jost WH.
    J Neural Transm (Vienna); 2023 Nov; 130(11):1337-1347. PubMed ID: 37210460
    [Abstract] [Full Text] [Related]

  • 8. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A, Jost WH.
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Drug therapy in Parkinson's disease].
    van Hilten JJ, Roos RA.
    Ned Tijdschr Geneeskd; 1999 Jan 30; 143(5):234-40. PubMed ID: 10086151
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P, Kubová D, Bareš M, Hortová H, Streitová H, Rektor I, Znojil V.
    Mov Disord; 2002 Jan 30; 17(1):188-91. PubMed ID: 11835461
    [Abstract] [Full Text] [Related]

  • 14. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1992 Nov 30; 55(11):1024-6. PubMed ID: 1469397
    [Abstract] [Full Text] [Related]

  • 15. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV, Katunina EA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013 Nov 30; 113(12):105-12. PubMed ID: 24596973
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H, Harder S, Bürklin F, Demisch L, Fischer PA.
    Clin Neuropharmacol; 1998 Nov 30; 21(2):86-92. PubMed ID: 9579293
    [Abstract] [Full Text] [Related]

  • 17. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
    Schelosky L, Poewe W.
    Acta Neurol Scand Suppl; 1993 Nov 30; 146():46-9. PubMed ID: 8101415
    [Abstract] [Full Text] [Related]

  • 18. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST, Woodward WR, Nutt JG.
    Clin Neuropharmacol; 1996 Feb 30; 19(1):59-64. PubMed ID: 8867518
    [Abstract] [Full Text] [Related]

  • 19. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA, Luquin MR, Vaamonde J, Grandas F, Martinez Lage JM.
    Can J Neurol Sci; 1987 Aug 30; 14(3 Suppl):488-92. PubMed ID: 3676922
    [Abstract] [Full Text] [Related]

  • 20. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Aug 30; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.